Advertisement
Article| Volume 32, ISSUE 5, P452-456, September 01, 1992

Cerebrospinal fluid neuropeptides in dementia

DOI:https://doi.org/10.1016/0006-3223(92)90132-J
Cerebrospinal fluid neuropeptides in dementia
Previous ArticleLateralized effects of diazepam on frontal brain electrical asymmetries in rhesus monkeys
Next ArticleAnger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Cerebrospinal fluid concentrations of corticotropin-releasing hormone (CRH), thyrotropin-releasing hormone (TRH) and somatostatin (SRIF) were measured in 77 female inpatients with moderate to extreme dementia and in 17 elderly female controls. Both multi-infarct (MID) and Alzheimer-type (SDAT) demented patients had equally elevated CSF CRH and TRH but not SRIF levels as compared with the controls. This elevation was, however, not seen in patients with simple dimentia while it was most prominent in those exhibiting marked depressive symptoms. It is concluded that depression rather than dementia itself may be associated with CSF CRH and TRH elevation in elderly patients with cognitive impairment.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Balldin J.
        • Gottfries C.G.
        • Karlsson I.
        • Lindstedt G.
        • Langström G.
        • Walinder J.
        Dexamethasone suppression test and serum prolactin in dementia disorders.
        Br J Psychiat. 1983; 143: 277-281
        • Ban T.A.
        Psychopharmacology for the Aged.
        in: Karger, Basel1980: 3-6
        • Banki C.M.
        • Bissette G.
        • Arato M.
        • O'Connor L.
        • Nemeroff C.B.
        CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia.
        Am J Psychiat. 1987; 144: 873-877
        • Banki C.M.
        • Bissette G.
        • Arato M.
        • Nemeroff C.B.
        Elevation of immunoreactive CSF TRH in depressed patients.
        Am J Psychiat. 1988; 145: 1526-1531
        • Bissette G.
        • Widerlöv E.
        • Walleus H.
        • Karlsson I.
        • Eklund K.
        • Forssman A.
        • Nemeroff C.B.
        Alterations in cerebrospinal fluid concentrations of somatostatin-like immunoreactivity in neuropsychiatric disorders.
        Arch Gen Psychiat. 1986; 43: 1148-1154
        • Carnes M.
        • Smith J.C.
        • Kalin N.H.
        • Bauwens S.F.
        The dexamethasone suppression test in demented outpatients with and without depression.
        Psychiat Res. 1983; 9: 337-344
        • Cockrell J.R.
        • Folstein M.
        Mini-mental state examination (MMSE).
        Psychopharm Bull. 1988; 24: 689-692
        • Coyle J.T.
        • Price D.L.
        • DeLong M.R.
        Alzheimer's disease: a disorder of cortical cholinergic innervation.
        Science. 1983; 219: 1184-1190
        • Crook R.
        Pharmacotherapy of cognitive deficits in Alzheimer's disease and age-associated memory impairment.
        Psychopharm Bull. 1988; 24: 25-29
        • Davidson M.
        • Stern R.G.
        • Bierer L.M.
        • Horvath T.B.
        • Zemishlani Z.
        • Markofsky R.
        • Mohs R.C.
        Cholinergic strategies in the treatment of Alzheimer's disease.
        Acta Psychiat Scan. 1991; : 47-51
        • De Jong J.A.
        • Roy A.
        Relationship of cognitive factors to CSF corticotropin-releasing hormone in depression.
        Am J Psychiat. 1990; 147: 350-352
        • Dillon W.R.
        • Goldstein M.
        Multivariate Analysis: Methods and Application.
        J. Wiley & Sons, New York1984
        • Kirkegaard C.
        • Faber J.
        • Hummer L.
        • Rogowski P.
        Increased levels of TRH in cerebrospinal fluid from patients with endogenous depression.
        Psychoneuroendocr. 1979; 4: 227-235
        • Kramer M.
        The rising pandemic of mental disorders and associated chronic diseases and disabilities.
        Acta Psychiat Scand. 1980; 62: 382-397
        • Lauter H.
        • Dame S.
        Depressive disorders and dementia: the clinical view.
        Acta Psychiat Scand. 1991; : 40-46
        • Mohs R.C.
        • Davies B.M.
        • Johns C.A.
        Oral physostigmine treatment of patients with Alzheimer's disease.
        Am J Psychiat. 1985; 142: 28-33
        • Nemeroff C.B.
        • Widerlöv E.
        • Bissette G.
        • Walleus H.
        • Karlsson I.
        • Eklund K.
        • Kilts C.D.
        • Loosen P.T.
        • Vale W.
        Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients.
        Science. 1984; 226: 1342-1344
        • Oram J.J.
        • Edwardsson J.
        • Millard P.H.
        Investigation of CSF neuropeptides in idiopathic senile dementia.
        Gerontol. 1981; 27: 216-223
        • Reding M.
        • Orto L.
        • Willensky P.
        • Fortuna I.
        • Day N.
        • Steiner S.F.
        • Gehr L.
        • McDowell F.
        The dexamethasone suppression test: an indicator of depression in stroke but not a predictor of rehabilitation outcome.
        Arch Neurol. 1985; 42: 209-212
        • Roy A.
        • Pickar D.
        • Paul S.
        • Doran A.
        • Chrousos G.P.
        • Gold P.W.
        CSF corticotropin-releasing hormone in depressed patients and normal control subjects.
        Am J Psychiat. 1987; 144: 641-645
        • Rubinow D.R.
        • Gold P.W.
        • Post R.M.
        • Ballenger J.C.
        • Cowdra R.W.
        Somatostatin in patients with effective illness and in normal volunteers.
        in: Post R.M. Ballenger J.C. Neurobiology of Mood Disorders. Williams & Wilkins, Baltimore1984: 369-387
        • Sagar S.M.
        • Beal F.
        • Marchall P.E.
        • Landis D.M.
        • Martin J.B.
        Implications of neuropeptides in neurological diseases.
        Peptides. 1984; 4: 255-262
        • Soininen H.S.
        • Jolkkonen J.T.
        • Reinikainen K.J.
        • Halonen T.D.
        • Riekkinen P.J.
        Reduced cholinesterase activity and somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with dementia of the Alzheimer type.
        J Neurol Sci. 1984; 63: 167-172
        • Wallin A.
        • Carlsson A.
        • Ekman R.
        • Gottfries C.G.
        • Karlsson I.
        • Svennerholm L.
        • Widerlöv E.
        Hypothalamic monoamines and neuropeptides in dementia.
        Eur Neuropsychopharm. 1991; 1: 165-168

      Article info

      Publication history

      Received in revised form: April 6, 1992
      Received: November 9, 1991

      Identification

      DOI: https://doi.org/10.1016/0006-3223(92)90132-J

      Copyright

      © 1992 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX